PAR 1.79% 27.5¢ paradigm biopharmaceuticals limited..

Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL, page-20

  1. 572 Posts.
    lightbulb Created with Sketch. 55
    Did PAR just re-do and pay for a study which someone else has done (and reasonably recently?). Looks like the real winners here are their CRO's. Gravy train going full tilt.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.